Clinical Trials Logo

Posterior Fossa Mutism clinical trials

View clinical trials related to Posterior Fossa Mutism.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02048176 Completed - Clinical trials for Posterior Fossa Mutism

Posterior Fossa Mutism on Quality of Life

Start date: July 2011
Phase: N/A
Study type: Observational

Posterior fossa mutism (PFM) occurs in up to 30% of patients after resection of a posterior fossa tumor, most commonly a medulloblastoma. PFM is characterized by delayed onset of mutism 1-6 days after surgery that can spontaneously improve on average from 7-8 weeks later. Few patients recover normal speech. Most of their speech continues to be marked by dysarthria, dysfluency and slowed rate. Researchers have not identified the pathophysiologic mechanism for PFM nor have they found a cure. Despite the improvements in speech, patients with PFM have shown multiple areas of neurocognitive deficits 12 months after diagnosis. Few studies have looked at long term outcomes of patients affected by PFM. We propose to survey patients who developed PFM after resection of a medulloblastoma to determine long term effects of PFM on patient's quality of life.